Administrative Core

阿拉伯联合酋长国银行CFAR使命：支持阿拉伯联合酋长国银行及其附属调查人员进行多学科调查， 在预防，发病机制，治疗，临床护理和心理社会方面的前沿研究 在美国和世界各地的艾滋病毒和相关疾病的表现。 UAB CFAR成立于1988年，是新NIH最初的七个特许中心之一。 倡议从一开始，UAB CFAR就在基础， 转化和临床艾滋病毒/艾滋病研究。随着开创性的研究发现， HIV-1病毒动力学、病毒多样性、HIV-1的人畜共患病起源以及转化治疗 研究导致了不少于7种抗逆转录病毒药物的首次人体试验，并最终获得FDA批准， UAB CFAR及其成员在领导艾滋病毒/艾滋病研究工作方面发挥了重要作用， 二十年来，全球范围内。值得注意的是，除了埃里克博士 亨特最近离开了该机构，该机构的核心科学领导层 UAB CFAR，包括Michael S.萨格（实验治疗和 现任CFAR主任），Beatrice H. Hahn（病毒发现和当前 CFAR Co-Director），乔治M. Shaw（病毒发病机制和当前CFAR 副主任）和凯西莫罗（分子病毒学和现任 CFAR副主任和发展核心领导人），一直保持 自UAB CFAR成立以来一直保持不变。这个领导小组有 带头并推动了一项重要的艾滋病毒/艾滋病研究议程， 二十年来，促进了新的招聘和发展， 艾滋病毒/艾滋病研究人员在UAB的一代。很明显， 这一修改后的应用是，UAB CFAR继续提供科学的 领导、方案协调、基本研究支助服务 科学方法、有效沟通、有针对性的 教师招聘，以及广泛工作的调查人员之间的联系 不同的研究领域，使UAB艾滋病毒/艾滋病研究的方式 在过去的二十年里，

UAB CFAR Mission: To support UAB and affiliated investigators in the conduct of multidisciplinary, cutting-edge research in the prevention, pathogenesis, therapeutics, clinical care, and psychosocial manifestations of HIV and related disorders in the United States and around the world. The UAB CFAR was established in 1988 as one of the original seven charter centers of a new NIH initiative. From the outset, the UAB CFAR has played a national and international leadership role in basic, translational, and clinical HIV/AIDS research. With seminal research discoveries spanning the gamut from HIV-1 viral dynamics to viral diversity to the zoonotic origins of HIV-1, and with translational therapeutics research leading to first-in-human trials, and ultimately FDA approval, of no fewer than 7 antiretroviral drugs, the UAB CFAR and its members have played an instrumental role in leading HIV/AIDS research efforts on a global scale for twenty years. Remarkably, with the exception of Dr. Eric Hunter who recently left the institution, the core scientific leadership of the UAB CFAR including Drs. Michael S. Saag (Experimental Therapeutics and current CFAR Director), Beatrice H. Hahn (Virus Discovery and current CFAR Co-Director), George M. Shaw (Viral Pathogenesis and current CFAR Associate Director), and Casey Morrow (Molecular Virology and current CFAR Associate Director and Developmental Core Leader), has remained intact since the inception of the UAB CFAR. This leadership group has spearheaded and nurtured a major HIV/AIDS research agenda for over twenty years and has fostered the recruitment and development of a new generation of HIV/AIDS investigators at UAB. What will become evident in this revised application is that the UAB CFAR continues to provide scientific leadership, programmatic coordination, essential research support services training in scientific methodologies, effective communication, targeted faculty recruitment, and linkages between investigators working in widely diverse areas of research in a manner that makes UAB HIV/AIDS research important today as it has been for the past twenty years